Dallah Healthcare sells its stake in Al-Faqih Company for 498 million riyals
In a significant strategic move reflecting the growing dynamism of the Saudi healthcare sector, Dallah Healthcare announced the signing of a binding agreement to sell its entire stake in Dr. Mohammed Bin Rashid Al-Faqih & Partners, amounting to approximately 31.21%. The transaction was completed in favor of Dr. Sulaiman Abdulqader Al-Faqih Hospital Company for a cash sum of approximately SAR 497.9 million.
This deal comes within a broader context of radical transformations in Saudi Arabia's healthcare sector, driven by the goals of Vision 2030, which aims to improve the quality of healthcare services and encourage private sector participation. Mergers, acquisitions, and strategic divestments among major medical companies, such as Dallah Healthcare and Fakieh Group, indicate market maturity and the efforts of large entities to enhance their operational efficiency and focus on key growth areas.
Background on the parties and the importance of the deal
Dallah Healthcare is one of the leading healthcare providers in the Kingdom, operating a vast network of hospitals and specialized medical centers. Dr. Sulaiman Faqih Hospitals Group, on the other hand, is a well-established medical entity with a strong reputation, particularly in the Western Region. This merger between the two entities through this transaction reflects a strategic repositioning in the market.
For Dallah Healthcare, the sale of this stake represents a step aimed at enhancing its financial efficiency and improving its capital structure. The company clarified that the proceeds from the sale will be used primarily to repay a portion of its existing Murabaha facilities, thereby easing its financial burden and allowing it greater flexibility in financing future expansion projects and focusing on its most profitable assets.
Expected impacts and regulatory requirements
Dallah Healthcare confirmed that the financial impact of the transaction will be positive on its financial results for the period in which the deal is completed. It noted that the target company is still in its expansion phase and its current contribution to the group's profitability is limited, making the decision to divest from it financially sound at this time.
However, the completion of the deal remains contingent upon fulfilling several preconditions, most importantly obtaining approval from the General Authority for Competition, a routine procedure in such large transactions to ensure they do not negatively impact market competition. Additionally, approvals from other parties contracting with the target company are required. Dallah confirmed that it will announce any material developments related to the transaction in due course, in accordance with applicable regulations.
